Beam Therapeutics Inc. (NASDAQ:BEAM) Q4 2025 Earnings Call Transcript
Operator: Good morning, and welcome to Beam Therapeutics Conference Call. [Operator Instructions] Please be advised that this call is being recorded at Beam's request.
Beam Therapeutics Inc. (BEAM)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | ARK Investment Management Catherine D. Wood | 12,467,189 | $345,590,488 | +13% | 2.29% |
| 2. | Farallon Capital Thomas Steyer | 10,063,111 | $278,949,437 | 1.32% | |
| 3. | Kynam Capital Derrick Tang | 2,440,214 | $67,642,732 | -4% | 4.32% |
| 4. | Casdin Capital Eli Casdin | 1,600,000 | $44,352,000 | 2.75% | |
| 5. | Redmile Group Jeremy Green | 1,285,859 | $35,644,011 | -8% | 2.62% |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $32.00 | 35,000 | $1,120,042.00 | 190,216 | 2026-02-24 | Filing | |
| $29.00 | 2,906 | $84,274.00 | 986,667 | 2026-01-30 | Filing | |
| $28.27 | 22,094 | $624,672.50 | 989,573 | 2026-01-30 | Filing | |
| $29.74 | 8,667 | $257,780.85 | 986,667 | 2026-01-29 | Filing | |
| $29.19 | 16,333 | $476,801.10 | 995,334 | 2026-01-29 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 11,909,138 | $330,121,317 | 0.02% | |
| 2. | 9,193,474 | $254,843,099 | 0% | |
| 3. | 8,450,182 | $234,239,046 | 0% | |
| 4. | 5,228,529 | $144,934,824 | 0% | |
| 5. | 4,540,132 | $125,852,459 | 19.31% |
News See All
Analyst Bullish on Beam Therapeutics (BEAM) Over Drug Program Trajectory
Beam Therapeutics Inc. (NASDAQ:BEAM) is one of the 13 hot stocks to buy with the highest upside potential. On February 9, Sami Corwin from William Blair maintained a Buy rating on Beam Therapeutics.
13 Hot Stocks to Buy with the Highest Upside Potential
On average, equities are expected continue to deliver positive results in 2026, this time with greater breadth across sectors, styles, and regions, compared to the other periods of the recent bull market...
Here is Why Beam Therapeutics (BEAM) Appears so Attractive
On January 22, Patrick Trucchio from H.C. Wainwright maintained a Buy rating on Beam Therapeutics (NASDAQ:BEAM), with a price target of $80.
17 Biotechnology Stocks with More Than 50% Upside
2025 was a year characterized by both challenges and opportunities for the biotechnology sector.
H.C. Wainwright Reiterated Buy on Beam Therapeutics (BEAM) After BEAM-302 FDA Expedited Approval
Beam Therapeutics Inc. (NASDAQ:BEAM) ranks among the best innovative stocks to buy according to Wall Street analysts. H.C.
13 Best Innovative Stocks to Buy According to Wall Street Analysts
Innovation is entering a new phase of rapid acceleration, according to ARK Invest.
Bernstein Maintains an Outperform Rating on Beam Therapeutics Inc. (BEAM)
On January 7, 2026, TheFly reported that Bernstein maintained its Outperform rating. It increased its price objective for Beam Therapeutics Inc. (NASDAQ:BEAM) from $37 to $41.
Growth Stock Portfolio: 12 Stock Picks By Cathie Wood
After a severe 2022 decline, Cathie Wood's flagship innovation fund witnessed a dramatic comeback through 2025, climbing 87.1% in the year ending in September 2025 and tripling over three years, according...
Beam Therapeutics Inc. (BEAM) Reports Updated Data From BEACON Phase 1/2 trial Of Ristoglogene
TheFly reported on December 2, 2025, that Beam Therapeutics Inc.
Hedge Fund Resource Center